Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy

References

• Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China, 2013. Cancer Lett. 2017;401:63–71.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–3551.
   PubMed Web of Science ®Google Scholar
• Wei Z, Ye X, Yang X, et al. Microwave ablation in combination with chemotherapy for the treatment of advanced non-small cell lung cancer. Cardiovasc Intervent Radiol. 2015;38:135–142.
   PubMed Web of Science ®Google Scholar
• Wei Z, Ye X, Yang X, et al. Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone. Med Oncol. 2015;32:464.
   PubMed Web of Science ®Google Scholar
• Zhong L, Sun S, Shi J, et al. Clinical analysis on 113 patients with lung cancer treated by percutaneous CT-guided microwave ablation. J Thorac Dis. 2017;9:590–597.
   PubMed Web of Science ®Google Scholar
• Wei Z, Yang X, Ye X, et al. Microwave ablation in combination with chemotherapy versus chemotherapy in advanced non small cell lung cancer. A prospective, randomized, phase III clinical trial. J Clin Oncol. 2017;35:abstracts 9048.
   Web of Science ®Google Scholar
• Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1improves myeloid dendritic cell-mediated antitumorimmunity. Nat Med. 2003;9:562–567.
   PubMed Web of Science ®Google Scholar
• Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–3044.
   PubMed Web of Science ®Google Scholar
• Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682–687.
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 2013;73:6900–6912.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015–3029.
   PubMed Web of Science ®Google Scholar
• Sheppard KA, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004;574:37–41.
   PubMed Web of Science ®Google Scholar
• Patsoukis N, Sari D, Boussiotis VA. PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressingCdc25A. Cell Cycle. 2012;11:4305–4309.
   PubMed Web of Science ®Google Scholar
• Charlton JJ, Chatzidakis I, Tsoukatou D, et al. Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner. J Immunol. 2013;190:6104–6114.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550.
   PubMed Web of Science ®Google Scholar
• Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35:3924–3933.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833.
   PubMed Web of Science ®Google Scholar
• Teng F, Meng X, Wang X, et al. Expressions of CD8 + TILs, PD-L1 and Foxp3 + TILs in stage I NSCLC guidingadjuvant chemotherapy decisions. Oncotarget. 2016;7:64318–64329.
   PubMedGoogle Scholar
• Song Z, Yu X, Zhang Y. Altered expression of programmed death-ligand 1 after neo-adjuvantchemotherapy in patients with lung squamous cell carcinoma. Lung Cancer. 2016;99:166–171.
   PubMed Web of Science ®Google Scholar
• Sun JM, Zhou W, Choi YL, et al. Prognostic significance of PD-L1 in patients with non-small cell lung cancer: a large cohort study of surgically resected cases. J Thorac Oncol. 2016;11:1003–1011.
   PubMed Web of Science ®Google Scholar
• Takada K, Toyokawa G, Okamoto T, et al. A comprehensive analysis of programmed cell death ligand-1 expression with the clone SP142 antibody in non-small-cell lung cancer patients. Clin Lung Cancer. 1997;18:95–82.
   Google Scholar
• Tokito T, Azuma K, Kawahara A, et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer. 2016;55:7–14.
   PubMed Web of Science ®Google Scholar
• Sorensen SF, Zhou W, Dolled-Filhart M, et al. PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy. Transl Oncol. 2016;9:64–69.
   PubMed Web of Science ®Google Scholar
• Rashed HE, Abdelrahman AE, Abdelgawad M, et al. Prognostic significance of programmed cell death ligand 1 (PD-L1), CD8+ tumor-infiltrating lymphocytes and p53 in Non-Small Cell Lung Cancer: An immunohistochemical study. Turk Patoloji Derg. 2017;1:211–222.
   PubMedGoogle Scholar
• Shi L, Chen L, Wu C, et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor. Clin Cancer Res. 2016;22:1173–1184.
   PubMed Web of Science ®Google Scholar
• Silvestrini MT, Ingham ES, Mahakian LM, et al. Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols. JCI Insight. 2017;2:e90521.
   PubMed Web of Science ®Google Scholar
• Ye X, Fan W, Wang H, et al. Expert consensus workshop report: Guidelines for thermal ablation of primary and metastatic lung tumors. J Can Res Ther. 2018;14:730–744.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria – a 10-year update. J Vasc Interv Radiol. 2014;25:1706–1705.
   PubMed Web of Science ®Google Scholar
• Jiang L, Su X, Zhang T, et al. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC). Oncotarget. 2017;8:26845–26857.
   PubMedGoogle Scholar
• Zhang P, Ma Y, Lv C, et al. Upregulation of programmed cell death Ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. Cancer Sci. 2016;107:1563–1571.
   PubMed Web of Science ®Google Scholar
• Yang X, Ye X, Huang G, et al. Repeated percutaneous microwave ablation for local recurrence of inoperable stage I nonsmall cell lung cancer. J Cancer Res Ther. 2017;13:683–688.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xu X, Ding J, et al. Dynamic changes of T-cell subsets and their relation with tumor recurrence after microwave ablation in patients with hepatocellular carcinoma. J Cancer Res Ther. 2018;14:40–45.
   PubMed Web of Science ®Google Scholar